Dr Kechagioglou joins the RTsafe Board at a time of significant international growth for the organisation, supporting its continued expansion of clinical services and innovation in radiation oncology.
A highly respected Clinical Oncologist and healthcare leader, Dr Kechagioglou brings extensive experience across clinical leadership, governance, innovation and patient-centred cancer care.
Her appointment further strengthens the collaboration between Icon Group and RTsafe, building on an established partnership focused on advancing the safety and precision of radiotherapy.
In 2025, Icon Group adopted RTsafe’s first-to-market PRIME technology across Australia to enhance quality assurance and support the safe delivery of complex radiosurgery treatments.
Dr Kechagioglou said the appointment reflects a shared commitment to the future of cancer care.
“RTsafe’s mission is closely aligned with what I believe is essential in modern cancer care: safety, precision, innovation, and a deep commitment to patients and clinical teams,” said Dr Kechagioglou.
“I look forward to contributing my experience in oncology, healthcare leadership, and service transformation to support RTsafe’s continued growth and its impact in radiation oncology worldwide.”
Icon continues to work in partnership with RTsafe to support clinicians with confidence in delivering advanced treatments, reinforcing our commitment to improving patient outcomes through innovation and global collaboration.
Icon Group is Australia’s largest dedicated cancer care provider and has expanded globally into New Zealand, Asia and the United Kingdom.
People from across Icon Group share their stories of success, career progression and being iconic.
At Icon, you’ll help change lives, every single day. In return for your passion, dedication and agility, we offer a workplace where you can.
Read the latest news and updates across Icon Group.